Table 2. Demographic and clinical characteristics of ESRD survival, ESRD death and control group.
| Variables | ESRD survival (N = 30) | ESRD death (N = 17) | HC (N = 30) |
|---|---|---|---|
| Age (year) | 55.9 ± 13.5b | 70.7 ± 9.0a | 59.3 ± 6.8 |
| Sex (M/F) | 30 (17/13) | 17 (9/8) | 30 (17/13) |
| Duration (months) | 30 ± 21 | 29 ± 22 | – |
| BMI (kg/m2) | 23.8 ± 3.2 | 21.5 ± 3.1 | 22.1 ± 1.5 |
| PTH (pg/mL) | 338.0 ± 104.1 | 240.8 ± 82.7 | – |
| CREA (μmol/L) | 939.3 ± 301.5a,b | 731.1 ± 206.8a | 65.4 ± 14.7 |
| BUN (mmol/L) | 22.2 ± 5.4a | 21.4 ± 7.5a | 5.2 ± 1.1 |
| UA (μmol/L) | 444.0 ± 99.6a | 442.4 ± 113.6a | 284.3 ± 66.7 |
| Ca (mmol/L) | 2.2 ± 0.2a | 2.2 ± 0.3a | 2.4 ± 0.2 |
| P (mmol/L) | 1.7 ± 0.4a | 1.6 ± 0.6a | 1.0 ± 0.1 |
| TG (mmol/L) | 2.2 ± 1.4a | 2.1 ± 1.1a | 1.1 ± 0.5 |
| CHOL (mmol/L) | 3.9 ± 0.8a | 3.7 ± 1.0a | 4.7 ± 0.5 |
| HDL-C (mmol/L) | 1.0 ± 0.4a | 1.0 ± 0.4a | 1.5 ± 0.3 |
| LDL-C (mmol/L) | 2.1 ± 0.7a | 1.7 ± 0.8a | 2.8 ± 0.5 |
| WBC (109/L) | 5.6 ± 1.4 | 5.7 ± 1.8 | 5.4 ± 1.3 |
| HGB (g/L) | 112.5 ± 16.0a | 103.8 ± 20.8a | 140 ± 19 |
| PLT (109/L) | 171.6 ± 67.1 | 144.2 ± 72.4a | 193.7 ± 50.6 |
| GLU (mmol/L) | 6.1 ± 3.5 | 6.9 ± 2.6 | 5.4 ± 0.9 |
| ALB (g/L) | 38.9 ± 4.2a | 38.4 ± 4.3a | 44.8 ± 3.0 |
| AST (U/L) | 15.6 ± 6.9b | 22.4 ± 11.4 | 18.1 ± 7.5 |
| ALT (U/L) | 12.8 ± 7.1 | 14.9 ± 9.5 | 15.7 ± 6.3 |
| ALP (U/L) | 95.1 ± 49.0 | 113.1 ± 50.5 | 92.2 ± 28.8 |
| TBIL (μmol/L) | 6.4 ± 1.8 | 7.2 ± 2.3 | 7.3 ± 2.3 |
| DBIL (μmol/L) | 3.2 ± 1.0 | 3.7 ± 1.2 | 3.3 ± 1.9 |
| TBA (ng/mL) | 2,888.83 ± 373.4a,b | 4,213.0 ± 785.7a | 1,849.2 ± 269.8 |
Notes:
Data represent means ± SD or means ± SEM. Comparisons performed via one-way ANOVA.
a
P < 0.05 vs. HC cohort.
b
P < 0.05 vs. ESRD death cohort.